Discontinuation of menopausal hormone therapy and risk of fracture: nested case-control studies using routinely collected primary care data.

ABSTRACT:

Background

Women benefit from reduced fracture risk while using menopausal hormone therapy. However, information on risks after stopping menopausal hormone therapy is scarce and inconsistent, with no information on longer-term fracture risk as women age. We aimed to produce robust estimates of fracture risk among past users for the longest possible period after discontinuing therapy.

Methods

We did a nested case-control study using UK primary and secondary care data from the Clinical Practice Research Datalink, with the underlying cohorts CPRD GOLD and Aurum. Women, aged 40 years and older, registered with a primary care practice between Jan 1, 1998, and Feb 28, 2023, and with a first record for any fracture, were matched at the fracture index date with up to five female con

SUBMITTER: Vinogradova Y 

PROVIDER: S-EPMC12316639 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature